{"id":"W1968735621","doi":"10.1016/s1470-2045(15)70027-6","title":"Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Takeda Oncology; GlaxoSmithKline; Public Health Agency; Astellas Pharma Canada; Novartis; Exelixis; Ministry of Education, Culture, Sports, Science and Technology; Bayer; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Prednisone; Prostate cancer; Abiraterone acetate; Internal medicine; Placebo; Clinical endpoint; Enzalutamide; Androgen deprivation therapy; Clinical trial; Population; Oncology; Cancer; Surgery; Urology; Pathology; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001102725,0.0003133045,0.001446408,0.0001428237,0.00009859286,0.00003991783,0.0001906573,0.0001030952,0.0001061943],"category_scores_gemma":[0.00008775408,0.0001641667,0.00009777016,0.0002978246,0.0002326985,0.0001235707,0.00003633724,0.0003978672,0.000018885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084946,"about_ca_system_score_gemma":0.002005257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004666987,"about_ca_topic_score_gemma":0.001124265,"domain_scores_codex":[0.9972979,0.0004661203,0.0005849799,0.0004063847,0.00055121,0.0006934291],"domain_scores_gemma":[0.9983804,0.0003164034,0.0003361125,0.0003961983,0.0003202288,0.0002506373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9855601,0.002453752,0.001738757,0.00006348491,0.0009401629,0.0001371201,0.005332638,0.0001790572,0.000113259,0.00001363343,0.001073619,0.002394463],"study_design_scores_gemma":[0.988126,0.007750344,0.0006194017,0.00008567672,0.0005466497,0.000006347105,0.0006112666,0.000575257,0.0002736872,0.00004174297,0.00118268,0.0001808898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729393,0.0006388988,0.00001816947,0.004810386,0.0002965484,0.02007692,0.0000696506,0.00004603255,0.001104083],"genre_scores_gemma":[0.9904562,0.0002718737,0.000300782,0.000491718,0.0003988003,0.005800022,0.0001778495,0.0000465653,0.002056164],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01751692,"threshold_uncertainty_score":0.6694525,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09142640043602607,"score_gpt":0.3987588878018678,"score_spread":0.3073324873658417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}